Skip to main content

Advertisement

SpringerLink
Log in

Superselective Intra-arterial Infusion Chemotherapy with Nedaplatin for Oral Cancer: A Pharmacological Study of the Dose Clearance

  • Research Paper
  • Published:
Journal of Maxillofacial and Oral Surgery Aims and scope Submit manuscript

Abstract

Introduction

Nedaplatin (cis-diammine-glycolate platinum) is a new anticancer agent developed in Japan. It is especially designed to reduce adverse side effects of CDDP such as renal toxicity and neurotoxicity.

Aim

We used nedaplatin as a superselective intra-arterial infusion chemotherapy for oral cancers and carried out a pharmacological study of the dose clearance of nedaplatin based on renal function as well as evaluating its efficacy, including hematological side effects.

Patients and Methods

Typical regimens of this chemotherapy consisted of 5-days straight of 24-h continuous intravenous infusion of 5-Fu with a single shot of nedaplatin via transfemoral artery on day 4. The dose of nedaplatin was calculated based on the 24-h creatine clearance. A total of 37 patients who had oral cancer and had received 68 courses (total) of chemotherapy were found to be eligible for this study.

Results

Total and free platinum concentrations in the plasma were measured at each of the time points, and the area under the curve (AUC, measured in units of µg h/ml) was calculated based on the platinum concentration with the following formula: CL (clearance of free platinum: l/h) = 0.042 × CCr (ml/min) + 5.84. The response rate was 70.1 % (in CR 51 %, in PR 19 %). Histological CR was seen in 28.6 % of surgical specimens. Moderate hematological side effects were seen. However, severe adverse events were not observed, including those associated with cannulation of the femoral artery.

Conclusion

The dose-clearance formula that was established by our study can most likely be utilized to accurately predict the optimal administered dose of nedaplatin for arterial infusion chemotherapy.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5

Similar content being viewed by others

References

  1. Drobnik J (1983) Antitumor activity of platinum complexes. Cancer Chemother Pharmacol 10:145–149

    Article  CAS  PubMed  Google Scholar 

  2. Suzumura Y, Kato T, Ueda R, Ota K (1989) Effect of treatment schedule on antitumor activity of glycolate-O,O′-diammineplatinum(II), a new platinum derivative: comparison with cis-diamminedichloroplatinum(II). Anticancer Res 9:1083–1088

    CAS  PubMed  Google Scholar 

  3. Inuyama Y, Miyake H, Horiuchi M, Hayasaki K, Komiyama S, Ota K (1992) A late phase II clinical study of cis-diammine glycolato platinum, 254-S, for head and neck cancers. Gan To Kagaku Ryoho 19:871–877

    CAS  PubMed  Google Scholar 

  4. Inuyama Y, Miyake H, Horiuchi M, Hayasaki K, Komiyama S, Ota K (1992) An early phase II clinical study of cis-diammine glycolato platinum, 254-S, for head and neck cancers. Gan To Kagaku Ryoho 19:863–869

    CAS  PubMed  Google Scholar 

  5. Sasaki Y, Amano T, Morita M, Shinkai T, Eguchi K, Tamura T, Ohe Y, Kojima A, Saijo N (1991) Phase I study and pharmacological analysis of cis-diammine(glycolato)platinum (254-S; NSC 375101D) administered by 5-day continuous intravenous infusion. Cancer Res 51:1472–1477

    CAS  PubMed  Google Scholar 

  6. Fukuda M, Shinkai T, Eguchi K, Sasaki Y, Tamura T, Ohe Y, Kojima A, Oshita F, Hara K, Saijo N (1990) Phase II study of (glycolate-O,O′) diammineplatinum(II), a novel platinum complex, in the treatment of non-small-cell lung cancer. Cancer Chemother Pharmacol 26:393–396

  7. Kanzawa F, Matsushima Y, Nakano H, Nakagawa K, Takahashi H, Sasaki Y, Saijo N (1988) Antitumor activity of a new platinum compound (glycolate-O,O′) diammineplatinum (II) (254-S), against non-small cell lung carcinoma grown in a human tumor clonogenic assay system. Anticancer Res 8:323–327

  8. Akaza H, Togashi M, Nishio Y, Miki T, Kotake T, Matsumura Y, Yoshida O, Aso Y (1992) Phase II study of cis-diammine(glycolato)platinum, 254-S, in patients with advanced germ-cell testicular cancer, prostatic cancer, and transitional-cell carcinoma of the urinary tract. 254-S Urological Cancer Study Group. Cancer Chemother Pharmacol 31:187–192

    Article  CAS  PubMed  Google Scholar 

  9. Maruoka Y, Ando T, Ogiuchi Y, Ogiuchi H (2007) Nedaplatin (NDP)-combination therapy (NDP/5-FU, NDP/S-1) for oral cancer. Gan To Kagaku Ryoho 34:713–717

    PubMed  Google Scholar 

  10. Ishii A, Korogi Y, Nishimura R, Kawanaka K, Yamura M, Ikushima I, Hirai T, Yamashita Y, Shinohara M (2004) Intraarterial infusion chemotherapy for head and neck cancers: evaluation of tumor perfusion with intraarterial CT during carotid arteriography. Radiat Med 22:254–259

    PubMed  Google Scholar 

  11. Fuwa N, Ito Y, Matsumoto A, Kamata M, Kodaira T, Furutani K, Sasaoka M, Kimura Y, Morita K (2000) A combination therapy of continuous superselective intraarterial carboplatin infusion and radiation therapy for locally advanced head and neck carcinoma. Phase I study. Cancer 89:2099–2105

    Article  CAS  PubMed  Google Scholar 

  12. Sileni VC, Fosser V, Maggian P, Padula E, Beltrame M, Nicolini M, Arslan P (1992) Pharmacokinetics and tumor concentration of intraarterial and intravenous cisplatin in patients with head and neck squamous cancer. Cancer Chemother Pharmacol 30:221–225

    Article  CAS  PubMed  Google Scholar 

  13. Sculier JP, Paesmans M, Thiriaux J, Lecomte J, Bureau G, Giner V, Koumakis G, Lafitte JJ, Berchier MC, Alexopoulos CG, Zacharias C, Mommen P, Ninane V, Klastersky J (1999) A comparison of methods of calculation for estimating carboplatin AUC with a retrospective pharmacokinetic-pharmacodynamic analysis in patients with advanced non-small cell lung cancer. European Lung Cancer Working Party. Eur J Cancer 35:1314–1319

    Article  CAS  PubMed  Google Scholar 

  14. Kanamori Y, Kigawa J, Minagawa Y, Irie T, Itamochi H, Cheng X, Okada M, Terakawa N (1997) Clinical responses and platinum concentrations in tumors after intra-arterial and intravenous administration of cisplatin in the same patients with cervical cancer. Gynecol Obstet Investig 44:57–60

    Article  CAS  Google Scholar 

  15. LeRoy AF, Wehling ML, Sponseller HL, Friauf WS, Solomon RE, Dedrick RL, Litterst CL, Gram TE, Guarino AM, Becker DA (1977) Analysis of platinum in biological materials by flameless atomic absorption spectrophotometry. Biochem Med 18:184–191

    Article  CAS  PubMed  Google Scholar 

  16. Gabrielsson J, Weiner D (1998) Pharmacokinetic and pharmacodynamic data analysis: concept & applications, 3rd edn. Swedish Pharmaceutical Press, Stockholm, pp 141–147

    Google Scholar 

  17. Sasaki Y, Shinkai T, Eguchi K, Tamura T, Ohe Y, Ohmori T, Saijo N (1991) Prediction of the antitumor activity of new platinum analogs based on their ex vivo pharmacodynamics as determined by bioassay. Cancer Chemother Pharmacol 27:263–270

    Article  CAS  PubMed  Google Scholar 

  18. Sasaki Y, Tamura T, Eguchi K, Shinkai T, Fujiwara Y, Fukuda M, Ohe Y, Bungo M, Horichi N, Niimi S et al (1989) Pharmacokinetics of (glycolate-0,0′)-diammine platinum (II), a new platinum derivative, in comparison with cisplatin and carboplatin. Cancer Chemother Pharmacol 23:243–246

    Article  CAS  PubMed  Google Scholar 

  19. Kigawa J, Minagawa Y, Itamochi H, Kanamori Y, Ishihara H, Terakawa N (1995) Platinum concentrations in uterus and serum after internal iliac arterial infusion of platinum compounds in rabbits. Obstet Gynecol 86:265–268

    Article  CAS  PubMed  Google Scholar 

  20. Frei E 3rd, Canellos GP (1980) Dose: a critical factor in cancer chemotherapy. Am J Med 69:585–594

    Article  PubMed  Google Scholar 

  21. Szluha K, Uzonyi I, Bascso J, Lampe L, Czifra I, Peter M, Villena C, Schmidt W (1995) Determination of Pt concentration in cervical tumor-tissues using energy-dispersive X-ray fluorescence (EDXRF) method. Microchem J 51:238–244

    Article  CAS  Google Scholar 

  22. Imai S, Kajihara Y, Munemori O, Kamei T, Mori T, Handa T, Akisada K, Orita Y (1995) Superselective cisplatin (CDDP)-carboplatin (CBDCA) combined infusion for head and neck cancers. Eur J Radiol 21:94–99

    Article  CAS  PubMed  Google Scholar 

  23. Ishibashi T, Yano Y, Oguma T (2005) Determination of optimal dosage for nedaplatin based on pharmacokinetic and toxicodynamic analysis. Anticancer Res 25:1273–1281

    CAS  PubMed  Google Scholar 

  24. Ishibashi T, Yano Y, Oguma T (2002) A formula for predicting optimal dosage of nedaplatin based on renal function in adult cancer patients. Cancer Chemother Pharmacol 50:230–236

    Article  CAS  PubMed  Google Scholar 

  25. Itamochi H, Kigawa J, Minagawa Y, Cheng X, Okada M, Terakawa N (1997) Antitumor effects of internal iliac arterial infusion of platinum compounds in a rabbit cervical cancer model. Obstet Gynecol 89:286–290

    Article  CAS  PubMed  Google Scholar 

  26. Ota K, Oguma T, Shimamura K (1994) Pharmacokinetics of platinum in cancer patients following intravenous infusion of cis-diammine(glycolato)platinum, 254-S. Anticancer Res 14:1383–1387

    CAS  PubMed  Google Scholar 

  27. Calvert AH, Newell DR, Gumbrell LA, O’Reilly S, Burnell M, Boxall FE, Siddik ZH, Judson IR, Gore ME, Wiltshaw E (1989) Carboplatin dosage: prospective evaluation of a simple formula based on renal function. J Clin Oncol 7:1748–1756

    CAS  PubMed  Google Scholar 

  28. Kurita H, Yamamoto E, Nozaki S, Wada S, Furuta I, Kurashina K (2004) Multicenter phase I trial of induction chemotherapy with docetaxel and nedaplatin for oral squamous cell carcinoma. Oral Oncol 40:1000–1006

    Article  CAS  PubMed  Google Scholar 

  29. Fuwa N, Kodaira T, Kamata M, Matsumoto A, Furutani K, Tachibana H, Ito Y (2002) Phase I study of combination chemotherapy with 5-fluorouracil (5-FU) and nedaplatin (NDP): adverse effects and recommended dose of NDP administered after 5-FU. Am J Clin Oncol 25:565–569

    Article  PubMed  Google Scholar 

  30. Duffull SB, Robinson BA (1997) Clinical pharmacokinetics and dose optimisation of carboplatin. Clin Pharmacokinet 33:161–183

    Article  CAS  PubMed  Google Scholar 

  31. Okamoto H, Nagatomo A, Kunitoh H, Kunikane H, Watanabe K (1998) Prediction of carboplatin clearance calculated by patient characteristics or 24-hour creatinine clearance: a comparison of the performance of three formulae. Cancer Chemother Pharmacol 42:307–312

    Article  CAS  PubMed  Google Scholar 

  32. Oya R, Nakamura S, Ikemura K, Takagi S, Mugino H (2004) AUC of Calvert’s formula in targeted intra-arterial carboplatin chemoradiotherapy for cancer of the oral cavity. Br J Cancer 90:2062–2066

    CAS  PubMed Central  PubMed  Google Scholar 

  33. Ohbayashi Y, Miyake M, Iwasaki A, Ogawa T, Nagahata S, Toyama Y, Ohkawa M (2004) Clinical study for determination of the dosage formula for intra-arterial infusion chemotherapy with nedaplatin. Gan To Kagaku Ryoho 31:713–716

    PubMed  Google Scholar 

  34. Ita M, Okafuji M, Fukuda K, Mitsuoka K, Hanakita T, Hayatsu Y (2003) Concurrent chemoradiotherapy with new platinum compound nedaplatin in oral cancer. Oral Oncol 39:144–149

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Oral and Maxillofacial Surgery, Faculty of Medicine, Kagawa University, 1750-1 Ikenobe, Miki-cho, Kita-gun, Kagawa, 761-0793, Japan

    Minoru Miyake, Yumiko Ohbayashi, Akinori Iwasaki & Fumi Sawai

  2. Department of Radiology, Faculty of Medicine, Kagawa University, Kagawa, Japan

    Yoshihiro Toyama & Yoshihiro Nishiyama

Authors
  1. Minoru Miyake
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Yumiko Ohbayashi
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Akinori Iwasaki
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Fumi Sawai
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Yoshihiro Toyama
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Yoshihiro Nishiyama
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Minoru Miyake.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Miyake, M., Ohbayashi, Y., Iwasaki, A. et al. Superselective Intra-arterial Infusion Chemotherapy with Nedaplatin for Oral Cancer: A Pharmacological Study of the Dose Clearance. J. Maxillofac. Oral Surg. 14, 616–623 (2015). https://doi.org/10.1007/s12663-014-0730-9

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12663-014-0730-9

Keywords

Search

Navigation